Arpraziquantel

Arpraziquantel ((R)-praziquantel) is the eutomer (the biologically active enantiomer) of praziquantel, a  medication which is under investigation for the treatment of schistosomiasis in young children with less side effects than the racemate.

Legal status
In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children. The applicant for this medicinal product is Merck Europe B.V. It is intended exclusively for markets outside the European Union.

Names
Arpraziquantel is the International nonproprietary name.